Drug-botanical interactions: a review of the laboratory, animal, and human data for 8 common botanicals.
Many Americans use complementary and alternative medicine (CAM) to prevent or alleviate common illnesses, and these medicines are commonly used by individuals with cancer.These medicines or botanicals share the same metabolic and transport proteins, including cytochrome P450 enzymes (CYP), glucuronosyltransferases (UGTs), and P-glycoprotein (Pgp), with over-the-counter and prescription medicines increasing the likelihood of drug-botanical interactions.This review provides a brief description of the different proteins, such as CYPs, UGTs, and Pgp.The potential effects of drug-botanical interactions on the pharmacokinetics and pharmacodynamics of the drug or botanical and a summary of the more common models used to study drug metabolism are described.The remaining portion of this review summarizes the data extracted from several laboratory, animal, and clinical studies that describe the metabolism, transport, and potential interactions of 8 selected botanicals. The 8 botanicals include black cohosh, Echinacea, garlic, Gingko biloba, green tea, kava, milk thistle, and St John's wort; these botanicals are among some of the more common botanicals taken by individuals with cancer.These examples are included to demonstrate how to interpret the different studies and how to use these data to predict the likelihood of a clinically significant drug-botanical interaction.
Shord
Stacy S
SS
College of Pharmacy, University of Illinois at Chicago, Chicago, IL 60612, USA. sshord@uic.edu
Shah
Kanan
K
Lukose
Alvina
A
D000818:Animals; D002986:Clinical Trials as Topic; D000529:Complementary Therapies / Q000009:adverse effects; D041743:Herb-Drug Interactions / Q000502:physiology*; D029001:Herbal Medicine; D006801:Humans